Novartis Ag (NVS) Cash from Financing Activities (2009 - 2025)

Novartis Ag (NVS) has 14 years of Cash from Financing Activities data on file, last reported at -$5.2 billion in Q2 2025.

• Quarterly Cash from Financing Activities fell 62.91% year-over-year to -$5.2 billion in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$17.2 billion (down 129.95% YoY) and the FY2025 annual result came in at -$14.9 billion, down 26.61% from the prior year.
• Cash from Financing Activities rose to -$5.2 billion in Q2 2025 per NVS's latest filing, from -$8.4 billion in the prior quarter.
• The five-year high for Cash from Financing Activities was -$382.0 million in Q3 2024, with the low at -$11.8 billion in Q4 2022.
• Average Cash from Financing Activities over 5 years is -$5.0 billion, with a median of -$3.5 billion recorded in 2023.
• Year-over-year, Cash from Financing Activities surged 95.81% in 2023 and slumped 1586.29% in 2024.
• Novartis Ag's Cash from Financing Activities stood at -$11.5 billion in 2021, then slipped by 3.18% to -$11.8 billion in 2022, then surged by 95.81% to -$496.0 million in 2023, then tumbled by 1586.29% to -$8.4 billion in 2024, then soared by 37.67% to -$5.2 billion in 2025.
• Business Quant data shows NVS's Cash from Financing Activities at -$5.2 billion in Q2 2025, -$8.4 billion in Q4 2024, and -$382.0 million in Q3 2024.